Audentes Therapeutics (BOLD) IPO Prices at $15, Middle of Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Audentes Therapeutics (BOLD) IPO Opens Up 27%
July 20, 2016 10:36 AM EDTToday's IPO for Audentes Therapeutics (NASDAQ: BOLD) opened for trading at $19 after pricing its initial public offering of 5,000,000 shares of its common stock at a price to the public of $15.00 per share, the middle of the expected $14.00-$16.00 range.
BofA Merrill Lynch, Cowen and Company and Piper Jaffray are acting as joint... More
